Does Zoloft Show Up on a Drug Test? Screening Guide

Quick answer: No. Zoloft (sertraline) is not a target drug on standard 5-, 10- or 12-panel urine drug tests, including DOT panels. It can occasionally trigger a false-positive benzodiazepine screen on some immunoassays, so any non-negative result should be confirmed by GC-MS or LC-MS/MS before action is taken.

• Sertraline is an SSRI antidepressant, not a controlled substance, and is not an analyte on common panels.
• The risk is cross-reactivity: sertraline has been reported in the literature to cause false-positive benzodiazepine immunoassay results.
• A screen is presumptive. Confirmation and a medical review process protect both the donor and your program.

What a standard drug test actually detects

Zoloft does not show up as itself on a routine screen because panels are built to detect specific drugs or metabolites, and sertraline is not among them. The federal workplace panel overseen by SAMHSA and used in DOT testing covers marijuana metabolite (THC), cocaine metabolite, amphetamines, opioids and phencyclidine (PCP). Expanded commercial panels add drugs such as benzodiazepines, barbiturates, methadone, and oxycodone.

Under the DOT/HHS 5-panel, initial test cutoffs include 50 ng/mL for marijuana metabolite, 150 ng/mL for cocaine metabolite, 25 ng/mL for PCP, and 2,000 ng/mL for opiates (codeine/morphine), per the HHS Mandatory Guidelines and DOT ODAPC. Benzodiazepines are not part of the federal 5-panel. On non-regulated panels, benzodiazepine cutoffs vary by product, commonly in the 200-300 ng/mL range, so check the package insert for the exact cutoff.

Where Zoloft can cause confusion

Instant urine tests are immunoassays: antibodies bind to a drug class, and a structurally similar compound can sometimes bind too. Published case reports describe sertraline (and its metabolite) producing false-positive benzodiazepine results on some immunoassay platforms. This is not universal and depends on the manufacturer, the antibody, and the cutoff. A donor taking sertraline will usually test negative.

The practical point for buyers: an instant result is presumptive, not final. Laboratory confirmation by gas or liquid chromatography with mass spectrometry distinguishes a true benzodiazepine from a cross-reacting medication.

Quick reference: medication vs. likely screen outcome

How to read and handle results step by step

1. Confirm the test was performed within the timeframe in the package insert (typically reading within about 5 minutes) and not read late.
2. Check the validity indicators: temperature on the cup (generally 90-100°F within 4 minutes) and any adulterant strips.
3. Read each drug line. In most cup and dip formats, a line in the test region means negative; no line means a presumptive non-negative. A missing control line means an invalid test.
4. Treat any non-negative as presumptive and preserve the specimen for confirmation.
5. Route confirmed positives to a medical review process before any employment, treatment, or court decision.

Choosing supplies when medications are a concern

If your clients take common psychiatric medications, product selection and procedure matter more than panel size. Programs that screen onsite can stock multi-panel urine drug test cups with integrated temperature strips and document a lab-confirmation path for every non-negative. Ask for the manufacturer's FDA clearance and CLIA-waiver status for each specific product, since these differ by device and panel, and keep that documentation on file. If you need help matching a panel to your program, contact American Screening Corp.

Program checklist

• Verify the cutoff (ng/mL) for every analyte on the product insert.
• Confirm FDA 510(k) and CLIA-waived status for each device you buy.
• Write a policy that treats instant results as presumptive.
• Arrange lab confirmation (GC-MS or LC-MS/MS) for all non-negatives.
• Offer donors a private way to disclose prescriptions, kept confidential.
• Train staff on reading windows, control lines and invalid results.
• Keep chain-of-custody and lot-number records.
• Review the policy against federal rules and state law, particularly the Americans with Disabilities Act where it may apply.

Why this matters for buyers

Acting on an unconfirmed result can lead to wrongful adverse actions, disputes, and avoidable legal exposure. A written confirmation protocol keeps clinics, courts, treatment centers, and employers defensible. Employers who pair testing with screening can also coordinate with Reveal Background checks as part of a consistent hiring process.

Frequently asked questions

Does Zoloft show up on a standard 10-panel drug test?

No. Sertraline is not a target analyte on standard 10-panel urine tests. The panel looks for specific drugs and metabolites, and an SSRI is not among them.

Can Zoloft cause a false positive?

Rarely. Case reports describe false-positive benzodiazepine immunoassay results with sertraline on some platforms. Confirm any presumptive positive by GC-MS or LC-MS/MS.

Does Zoloft affect DOT drug tests?

DOT panels test for marijuana, cocaine, amphetamines, opioids, and PCP, not sertraline or benzodiazepines, so Zoloft is not expected to produce a DOT positive.

What should we do with a non-negative result for a donor on Zoloft?

Treat it as presumptive, send the specimen for laboratory confirmation, and use a medical review process before any decision.

Sources

• SAMHSA: Workplace Drug Testing
• U.S. DOT: Office of Drug and Alcohol Policy and Compliance
• MedlinePlus (NIH): Sertraline

This article is general information, not legal or medical advice.